Procarbazine Hydrochloride Capsules Hodpro Matulan

[Product Name] Procarbazine Hydrochloride Capsules

[English Name] Procarbazine Hydrochloride Capsules

[Specification] 50 mg × 50 capsules/box

[Manufacturer] Neon Laboratories Ltd.

[Indications]

This product is one of the primary drugs in the standard MOPP and COPP regimens for malignant lymphoma. It also demonstrates certain efficacy against small cell lung cancer (SCLC), malignant melanoma, multiple myeloma, and brain tumors (primary or secondary).

[Dosage and Administration]

Oral administration. For adults, the standard dose is 50 mg taken three times daily; alternatively, the entire daily dose may be taken as a single dose at bedtime to alleviate gastrointestinal side effects. Treatment is administered continuously for two weeks, followed by a four-week rest period before repeating the cycle. Treatment should be discontinued if the leukocyte count falls below 3.0 × 10⁹/L or the platelet count falls below 80–100 × 10⁹/L. Once blood counts have recovered, the dosage should be reduced to 50–100 mg per day.

[Adverse Reactions]

1. Bone marrow suppression is the dose-limiting toxicity; it can lead to leukopenia and thrombocytopenia. This effect typically appears relatively late—generally 4 to 6 weeks after initiating treatment—and usually resolves within 2 to 3 weeks thereafter.

2. Nausea, vomiting, and anorexia are common. Occasional adverse effects include stomatitis, dry mouth, diarrhea, constipation, dizziness, drowsiness, mental confusion, and abnormal electroencephalograms (EEGs). Rare adverse effects include hepatic impairment, dermatitis, skin hyperpigmentation, alopecia, and peripheral neuritis.

[Contraindications]

Not yet established.

[Precautions]

Liver and kidney function should be monitored regularly. Dosage reductions are recommended for patients with hepatic or renal insufficiency, diabetes (as this product may potentiate the effects of hypoglycemic agents), severe infections, or those who have recently undergone radiotherapy or chemotherapy.

[Drug Interactions]

This product should not be used concomitantly with imipramine, guanethidine, reserpine, or similar agents, as this may exacerbate their hypotensive effects. This product may potentiate the effects of barbiturates, anesthetics (such as thiopental sodium), and antihistamines. Concomitant use with curare-like neuromuscular blocking agents may enhance muscle relaxation, potentially leading to respiratory distress. Furthermore, as this product may potentiate the effects of hypoglycemic agents, their concomitant use should be avoided whenever possible. [Pharmacological Action]

This product is a derivative of hydrazine; while it possesses no intrinsic anti-cancer activity, its metabolites *in vivo* exert an alkylating effect, classifying it as an atypical alkylating agent. Through oxidation by hepatic microsomal enzymes, the drug releases methyl cations (CH₃⁺) which bind to DNA, causing its depolymerization. Furthermore, it methylates DNA precursors—thymidylic acid and guanylic acid—thereby inhibiting RNA and protein synthesis, interfering with tumor cell proliferation, and blocking cells in the S-phase of the cell cycle from entering the G2-phase.

[Storage]

Protect from light; keep tightly sealed and store at room temperature.

[Product Specifications]

Product Name: Nazhiliang (Hodpro/Matulan) Procarbazine Hydrochloride Capsules — 50 mg × 50 Capsules/Box

Synonyms: Methylbenzylhydrazine, Procarbazine, Isopropylaminobenzylhydrazine

Common Name: Procarbazine Hydrochloride Capsules

Composition: Procarbazine

Dosage Form: Capsules

Specification: 50 mg × 50 Capsules/Box

Manufacturer: Neon Laboratories Ltd.

Indications: This product is one of the primary components of the standard MOPP and COPP regimens for the treatment of malignant lymphoma. It also demonstrates therapeutic efficacy against small cell lung cancer (SCLC), malignant melanoma, multiple myeloma, and brain tumors (both primary and secondary).

Dosage and Administration:Oral administration. For adults, the standard dose is 50 mg taken three times daily; alternatively, the entire daily dose may be taken as a single dose at bedtime to mitigate gastrointestinal side effects. Treatment is administered continuously for two weeks, followed by a four-week rest period before repeating the cycle. Treatment should be discontinued if the leukocyte count falls below 3.0 × 10⁹/L or the platelet count falls below 80–100 × 10⁹/L. Once blood counts have recovered, the dosage should be reduced to 50–100 mg per day.